Search research articles
Contact Us
Filters
Showing results (21-30 of 45) with videos related to
Page
of 5
Sort By:
Cancer Research
|
August 26, 2010
Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4
Shunbin Xiong, Vinod Pant, Young-Ah Suh, et al.
Frontiers in Immunology
|
April 29, 2021
The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies
Prerna Malaney, María Velasco-Estevez, Pedro Aguilar-Garrido, et al.
The Journal of Pathology
|
June 4, 2014
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer
Alfonso Quintás-Cardama, Sean M Post, Luisa M Solis, et al.
Cancer Research
|
October 11, 2011
Multiple stress signals activate mutant p53 in vivo
Young-Ah Suh, Sean M Post, Ana C Elizondo-Fraire, et al.
Plos One
|
June 4, 2010
Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations
Shenying Fang, Ralf Krahe, Guillermina Lozano, et al.
Haematologica
|
September 16, 2017
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
Peter P Ruvolo, Huaxian Ma, Vivian R Ruvolo, et al.
Cancer Cell
|
September 14, 2010
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development
Sean M Post, Alfonso Quintás-Cardama, Vinod Pant, et al.
Acta Haematologica
|
December 12, 2025
Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study
Margaret T Kasner, Nigel Courtenay-Luck, Courtney DiNardo, et al.
Proteomics. Clinical Applications
|
January 17, 2019
Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse
Fieke W Hoff, Chenyue W Hu, Amina A Qutub, et al.
Journal for Immunotherapy of Cancer
|
July 30, 2021
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML
Shelley Herbrich, Natalia Baran, Tianyu Cai, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 45) with videos related to
Sort By:
Page
of 5
Cancer Research
|
August 26, 2010
Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4
Shunbin Xiong, Vinod Pant, Young-Ah Suh, et al.
Frontiers in Immunology
|
April 29, 2021
The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies
Prerna Malaney, María Velasco-Estevez, Pedro Aguilar-Garrido, et al.
The Journal of Pathology
|
June 4, 2014
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer
Alfonso Quintás-Cardama, Sean M Post, Luisa M Solis, et al.
Cancer Research
|
October 11, 2011
Multiple stress signals activate mutant p53 in vivo
Young-Ah Suh, Sean M Post, Ana C Elizondo-Fraire, et al.
Plos One
|
June 4, 2010
Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations
Shenying Fang, Ralf Krahe, Guillermina Lozano, et al.
Haematologica
|
September 16, 2017
Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
Peter P Ruvolo, Huaxian Ma, Vivian R Ruvolo, et al.
Cancer Cell
|
September 14, 2010
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development
Sean M Post, Alfonso Quintás-Cardama, Vinod Pant, et al.
Acta Haematologica
|
December 12, 2025
Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study
Margaret T Kasner, Nigel Courtenay-Luck, Courtney DiNardo, et al.
Proteomics. Clinical Applications
|
January 17, 2019
Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse
Fieke W Hoff, Chenyue W Hu, Amina A Qutub, et al.
Journal for Immunotherapy of Cancer
|
July 30, 2021
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML
Shelley Herbrich, Natalia Baran, Tianyu Cai, et al.
Page
of 5